Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant GM2-KLH/QS-21 Vaccination vs Observation in Stage II Melanoma
NCT00005052Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 1999
- Modality
- Recombinant Proteins and Enzymes, Liposomes, Split/Subunit Vaccines
- Countries
- 18
01
Overview
A Phase 3 trial of gm2-klh, QS-21 in melanoma, sponsored by European Organisation for Research and Treatment of Cancer. Status: unknown.
02
Drugs
gm2-klhQS-21
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00005052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005052.